Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine developmentIntravacc has IP and know-how in vaccine conjugation and manufacturing of carrier protein based...
BILTHOVEN, The Netherlands, March 28, 2024 (GLOBE NEWSWIRE) -- Intravacc, a leading global contract development and manufacturing organization (CDMO) specializing in infectious disease and therapeutic vaccines, and Primrose Bio, a biotechnology company with leading technologies that improve the manufacturing of next-generation therapeutics, announced a strategic partnership to enhance the development and supply of conjugate vaccines. Third parties engaged in developing conjugate vaccines will have access to a seamless solution for vaccine conjugation, manufacturing and supply.
Intravacc announces positive data of intranasal OMV based vaccine for SARS-CoV-2
Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine
Intravacc's new website offers an immersive user experience, showcasing their CDMO expertise vaccine platforms and a hub for scientific publications.
Intravacc and Sanquin Diagnostic Services optimized the in vitro Monocyte Activation Test (MAT) for OMV vaccinesMAT test potential replacement for the traditional rabbit pyrogen testing (RPT) for...
Mucosal route induces both localized and systemic immunityIntravacc is currently developing 3 OMV-based intranasal vaccinesArticle published in peer-reviewed journal ˜Current Opinions in Immunology™ ...
BILTHOVEN, Netherlands, Feb. 23, 2023 /PRNewswire/ -- Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced the appointment of Prof. Dr. Virgil Schijns as Visiting Professor at the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) of the University of Strathclyde in Glasgow, for a period of three years effective February, 2023.
BILTHOVEN, The Netherlands, Jan. 16, 2023 /PRNewswire/ -- Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced favorable pre-clinical data for Avacc 11®, the prophylactic intranasal gonorrhea candidate vaccine Intravacc develops in partnership with Therapyx inc.. The results of the candidate, a proprietary outer membrane vesicle (OMV) platform-based gonorrhea vaccine combined with encapsulated IL-12, showed protection against subsequent infection with Neisseria gonorrhea (NG). Results were published in the peer reviewed journal MSphere of the American Society of Microbiology. In October 2022, Intravacc was awarded a $14.6 Million NIH/NIAID contract to further develop this intranasal candidate gonorrhea vaccine.
BILTHOVEN, The Netherlands, Nov. 30, 2022 /PRNewswire/ -- Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced that it enrolled the first participant in a phase I first in-human clinical trial of Avacc 10®, the company's SARS-CoV-2 intranasal subunit vaccine, as a booster to previous COVID-19 vaccinations. Avacc 10® is based on Intravacc's proprietary outer membrane vesicles (OMV) platform.